<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plospath</journal-id>
      <journal-title-group>
        <journal-title>PLoS Pathogens</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1553-7366</issn>
      <issn pub-type="epub">1553-7374</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">PPATHOGENS-D-12-02001</article-id>
      <article-id pub-id-type="doi">10.1371/journal.ppat.1003265</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Immunology</subject>
          </subj-group>
          <subj-group>
            <subject>Microbiology</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Global health</subject>
          </subj-group>
          <subj-group>
            <subject>Infectious diseases</subject>
          </subj-group>
          <subj-group>
            <subject>Public health</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Immunology</subject>
          <subject>Infectious Diseases</subject>
          <subject>Public Health and Epidemiology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Dengue Virus Co-opts UBR4 to Degrade STAT2 and Antagonize Type I Interferon Signaling</article-title>
        <alt-title alt-title-type="running-head">Dengue Virus Co-opts UBR4 to Degrade STAT2</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Morrison</surname>
            <given-names>Juliet</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Laurent-Rolle</surname>
            <given-names>Maudry</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Maestre</surname>
            <given-names>Ana M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Rajsbaum</surname>
            <given-names>Ricardo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Pisanelli</surname>
            <given-names>Giuseppe</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Simon</surname>
            <given-names>Viviana</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Mulder</surname>
            <given-names>Lubbertus C. F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Fernandez-Sesma</surname>
            <given-names>Ana</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>García-Sastre</surname>
            <given-names>Adolfo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>Department of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Diamond</surname>
            <given-names>Michael S.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>Washington University School of Medicine, United States of America</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">adolfo.garcia-sastre@mssm.edu</email></corresp>
        <fn fn-type="conflict">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: JM MLR AGS. Performed the experiments: JM MLR AMM GP RR. Analyzed the data: JM MLR RR AMM GP AGS AFS LCFM VS. Contributed reagents/materials/analysis tools: JM MLR AMM GP AGS AFS LCFM. Wrote the paper: JM MLR AGS.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>3</month>
        <year>2013</year>
      </pub-date>
      <volume>9</volume>
      <issue>3</issue>
      <elocation-id>e1003265</elocation-id>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>8</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>2</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Morrison et al</copyright-holder>
        <license xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>An estimated 50 million dengue virus (DENV) infections occur annually and more than forty percent of the human population is currently at risk of developing dengue fever (DF) or dengue hemorrhagic fever (DHF). Despite the prevalence and potential severity of DF and DHF, there are no approved vaccines or antiviral therapeutics available. An improved understanding of DENV immune evasion is pivotal for the rational development of anti-DENV therapeutics. Antagonism of type I interferon (IFN-I) signaling is a crucial mechanism of DENV immune evasion. DENV NS5 protein inhibits IFN-I signaling by mediating proteasome-dependent STAT2 degradation. Only proteolytically-processed NS5 can efficiently mediate STAT2 degradation, though both unprocessed and processed NS5 bind STAT2. Here we identify UBR4, a 600-kDa member of the N-recognin family, as an interacting partner of DENV NS5 that preferentially binds to processed NS5. Our results also demonstrate that DENV NS5 bridges STAT2 and UBR4. Furthermore, we show that UBR4 promotes DENV-mediated STAT2 degradation, and most importantly, that UBR4 is necessary for efficient viral replication in IFN-I competent cells. Our data underscore the importance of NS5-mediated STAT2 degradation in DENV replication and identify UBR4 as a host protein that is specifically exploited by DENV to inhibit IFN-I signaling via STAT2 degradation.</p>
      </abstract>
      <abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>Dengue virus (DENV) is the leading cause of mosquito-borne viral illness and death in humans. At present, there are no vaccines and no specific antiviral therapeutics to prevent or treat DENV infections. We previously described that the NS5 protein of DENV inhibits type I interferon signaling in virus-infected cells by mediating STAT2 degradation. This property allows DENV to overcome the antiviral effects of type I interferon, contributing to viral replication in the host. We have now obtained new insight into the mechanism by which DENV NS5 induces STAT2 degradation. NS5 bridges STAT2 with the cellular protein UBR4, a member of a family of predicted E3 ligases, resulting in UBR4-mediated STAT2 degradation. Elimination of UBR4 or mutations in NS5 that prevent its binding to UBR4 prevent NS5 from inducing STAT2 degradation. Importantly, UBR4 is required for optimal DENV replication in the presence of a competent type I interferon system. Our data demonstrate the requirement of a host factor, UBR4, for DENV to overcome the antiviral interferon response. This information might be important for the design of specific DENV inhibitors that prevent dengue virus from evading innate immunity.</p>
      </abstract>
      <funding-group>
        <funding-statement>Support was provided to AG-S by Northeast Biodefense Center, an NIAID funded Research Center of Excellence, grant U54AI057158, ML-R by NIH fellowship FAI077333A, VS by NIH-NIAID grants R01 AI089246 and P01AI090935, LCFM by NIH-NIAID grant 5R21AI096943, AF-S by NIH-NIAID grants 1R01AI073450 and P01AI090935 and DARPA grant HR0011-11-C-0094. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
      </funding-group>
      <counts>
        <page-count count="13"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Approximately fifty million dengue virus (DENV) infections occur annually with more than forty percent of the human population at risk of developing dengue fever (DF) or dengue hemorrhagic fever (DHF). DF and its more severe form, DHF, are potentially fatal diseases caused by the four serotypes (1, 2, 3 and 4) of DENV <xref ref-type="bibr" rid="ppat.1003265-Chen1">[1]</xref>. As no approved vaccines or antiviral therapeutics are available for the prevention or treatment of DENV infections, it is imperative that the biology and immunology of DENV infections are better understood. An in depth comprehension of DENV-host interactions will accelerate our progress in developing DENV therapeutics.</p>
      <p>DENV, along with other clinically relevant arboviruses such as West Nile virus (WNV), Japanese encephalitis virus (JEV) and yellow fever virus (YFV), belongs to the flavivirus genus of the <italic>Flaviviridae</italic> family. The flavivirus genome is a capped 11 kb genome that is translated into a single polyprotein, which is cleaved both by the viral protease (NS2B/3) and host proteases to yield three structural proteins (capsid [C], membrane [prM/M] and envelop [E]) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) <xref ref-type="bibr" rid="ppat.1003265-Rice1">[2]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Coia1">[3]</xref>. The flavivirus structural proteins incorporate the viral genome into newly generated virions while the non-structural proteins replicate the viral genome and exploit the cellular machinery to subvert host immune responses. The approximately 900-amino-acid NS5 protein is the largest and most conserved flavivirus protein <xref ref-type="bibr" rid="ppat.1003265-Lindenbach1">[4]</xref>. This multifunctional protein has RNA-dependent RNA polymerase (RdRp) activity as well as methyltransferase activity <xref ref-type="bibr" rid="ppat.1003265-Chu1">[5]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Egloff1">[6]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Zhou1">[7]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Issur1">[8]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Daffis1">[9]</xref>. In addition, more recent studies have shown that NS5 is a potent interferon-signaling antagonist <xref ref-type="bibr" rid="ppat.1003265-Best1">[10]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Lin1">[11]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Werme1">[12]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Mazzon1">[14]</xref>, <xref ref-type="bibr" rid="ppat.1003265-LaurentRolle1">[15]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Morrison1">[16]</xref>.</p>
      <p>The significance of the interferon (IFN) response as an important component of host immunity is underscored by numerous examples of viruses that antagonize it <xref ref-type="bibr" rid="ppat.1003265-Li1">[17]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Miller1">[18]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Parisien1">[19]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Parisien2">[20]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Vidy1">[21]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Mackenzie1">[22]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Morrison2">[23]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Valmas1">[24]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Hollidge1">[25]</xref>. Viruses express pathogen-associated molecular patterns (PAMPs) that trigger the production of type I IFN (IFNα/β or IFN-I) <xref ref-type="bibr" rid="ppat.1003265-Thompson1">[26]</xref>. Binding of IFN-I to the cell-surface IFN-I receptor (IFNAR) initiates a signaling cascade that results in the activation and phosphorylation of the Janus kinases, Jak1 and Tyk2, and the transcription factors, STAT1 and STAT2. Phosphorylated STAT1 and STAT2 along with IRF9 form the heterotrimeric transcriptional complex, ISGF3 <xref ref-type="bibr" rid="ppat.1003265-Stark1">[27]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Schindler1">[28]</xref>, and induce the expression of antiviral IFN-stimulated genes (ISGs) <xref ref-type="bibr" rid="ppat.1003265-Der1">[29]</xref>, <xref ref-type="bibr" rid="ppat.1003265-deVeer1">[30]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Schoggins1">[31]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Schoggins2">[32]</xref>.</p>
      <p>DENV encodes several antagonists of both IFN-I production and IFN-I signaling <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Mazzon1">[14]</xref>, <xref ref-type="bibr" rid="ppat.1003265-RodriguezMadoz1">[33]</xref>, <xref ref-type="bibr" rid="ppat.1003265-RodriguezMadoz2">[34]</xref>, <xref ref-type="bibr" rid="ppat.1003265-MunozJordan1">[35]</xref>, <xref ref-type="bibr" rid="ppat.1003265-MunozJordan2">[36]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Jones1">[37]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Ho1">[38]</xref>. The NS5 proteins of DENV and other flaviviruses have been shown to be potent inhibitors of IFN signaling. NS5 proteins of different flaviviruses may target different steps of the IFN signaling pathway. For example, WNV NS5 prevents the phosphorylation of the STAT proteins, while DENV NS5 binds human STAT2 and promotes its proteasomal degradation <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003265-LaurentRolle1">[15]</xref>.</p>
      <p>Although STAT degradation is a common mechanism of viral IFN antagonism <xref ref-type="bibr" rid="ppat.1003265-Parisien1">[19]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Parisien2">[20]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Young1">[39]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Andrejeva1">[40]</xref>, the requirements for DENV NS5-mediated STAT2 degradation are unique. DENV NS5-mediated STAT2 degradation requires NS5 to be proteolytically cleaved at its N terminus from a larger precursor protein <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. N-terminal cleavage of NS5 normally occurs during DENV infection because the NS2B/3 protease cleaves at the junction located between NS4B and NS5 thereby releasing NS5 from the viral polyprotein <xref ref-type="bibr" rid="ppat.1003265-Chambers1">[41]</xref>. Though both unprocessed and proteolytically-processed NS5 can bind STAT2, only processed NS5 can efficiently mediate STAT2 degradation <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. Furthermore, the first ten amino acids of NS5 are dispensable for STAT2 binding but are indispensable for STAT2 degradation <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. While the viral requirements for DENV-mediated STAT2 degradation are known, the cellular components were unspecified until now.</p>
      <p>This study identifies the 600-kDa protein, UBR4, as a binding partner of DENV NS5. UBR4 is a member of the N-recognin family, which contains proven and predicted E3 ligases that recognize and degrade proteins containing destabilizing N termini <xref ref-type="bibr" rid="ppat.1003265-Tasaki1">[42]</xref>. UBR4 interacts preferentially with proteolytically-processed DENV NS5 but not with YFV NS5 or WNV NS5, highlighting the specificity of the DENV NS5/UBR4 interaction. Furthermore, we have identified two residues within the first 10 N-terminal amino acids of NS5, threonine 2 and glycine 3, that are required for NS5 binding to UBR4. These two residues are conserved across the four DENV serotypes but are not found in other flaviviruses. Finally, we show that UBR4 is required for DENV-mediated STAT2 degradation, and for efficient DENV replication in IFN-I competent cells. Our data confirm the importance of NS5-mediated STAT2 degradation for DENV replication, and identify UBR4 as a host protein that is specifically co-opted by DENV to inhibit IFN-I signaling via STAT2 degradation.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>DENV NS5 binds UBR4</title>
        <p>DENV NS5 binds human and non-human primate STAT2 but cannot efficiently mediate STAT2 degradation unless it is expressed in the context of a precursor protein from which it is N-terminally cleaved <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. When DENV NS5 is engineered to be expressed downstream of ubiquitin, cellular hydrolases cleave ubiquitin in a manner that mimics the cleavage of NS4B away from NS5 by the NS2B/3 protease during DENV infection <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. To identify host proteins that are required for NS5-mediated degradation of STAT2, we generated a DENV2 NS5 construct consisting of RFP-ubiquitin fused to the NS5 N-terminus and a TAP (tandem-affinity purification) tag fused to the NS5 C-terminus. This NS5 construct was expressed in 293T cells, in the presence or absence of human STAT2-FLAG, and then purified using the TAP method. A high molecular weight protein band was consistently and specifically co-precipitated with NS5 both in the presence and absence of overexpressed STAT2 (<xref ref-type="fig" rid="ppat-1003265-g001">Figure 1A</xref>). Trypsin digestion of this band yielded five peptides that were identified by mass spectrometry as sequences of the N-recognin, UBR4 (<xref ref-type="table" rid="ppat-1003265-t001">Table 1</xref>) <xref ref-type="bibr" rid="ppat.1003265-Tasaki1">[42]</xref>. To confirm the binding and specificity of the interaction between DENV2 NS5 and UBR4, HA-tagged DENV2 NS5, DENV1 NS5, and YFV NS5 were expressed in 293T cells and purified by immunoprecipitation with antibodies raised against the HA epitope. The NS5 protein of both DENV1 and DENV2 precipitated UBR4 from 293T cells but YFV NS5 was unable to precipitate UBR4 from these cells (<xref ref-type="fig" rid="ppat-1003265-g001">Figure 1B</xref>). WNV NS5 was also unable to bind UBR4 (<xref ref-type="fig" rid="ppat-1003265-g001">Figure 1C</xref>). In order to assess the specificity of DENV NS5 for UBR4, we also examined the ability of NS5 to bind another member of the N-recognin family, UBR5. DENV1 and DENV2 NS5 bound UBR4 but not UBR5, further highlighting the unique interaction between UBR4 and DENV NS5 (<xref ref-type="fig" rid="ppat-1003265-g001">Figure 1B</xref>).</p>
        <fig id="ppat-1003265-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.ppat.1003265.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>DENV NS5 binds UBR4.</title>
            <p>(A) RFP-ubiquitin-NS5-TAP was expressed in 293T cells, in the presence or absence of human STAT2-FLAG, and then purified using the tandem affinity purification (TAP) method. The purified proteins were resolved on an SDS 4–15% gel that was then stained with silver. *NS5 and STAT2 run in similar positions in the gel. The bands highlighted by the arrows were analyzed by mass spectrometry at Taplin Biological Mass Spectrometry Facility, Harvard Medical School. (B and C) HA-tagged DENV2, DENV1, WNV and/or YFV NS5 proteins were immunoprecipitated from 293T cells using anti-HA beads. Immunoblot (IB) analysis of the immunoprecipitate (IP) and whole cell extract (WCE) was performed against UBR4, UBR5, STAT2, HA and/or β-tubulin.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003265.g001" position="float" xlink:type="simple"/>
        </fig>
        <table-wrap id="ppat-1003265-t001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.ppat.1003265.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>UBR4 peptides identified by mass spectrometry.</title>
          </caption>
          <alternatives>
            <graphic id="ppat-1003265-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003265.t001" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Peptide sequence</td>
                  <td align="left" rowspan="1" colspan="1">Position in UBR4 protein (NCBI Accession # Q5T4S7)</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <named-content content-type="gene" xlink:type="simple">RISESLVRH</named-content>
                  </td>
                  <td align="left" rowspan="1" colspan="1">1750–1758</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <named-content content-type="gene" xlink:type="simple">KSFAATISRT</named-content>
                  </td>
                  <td align="left" rowspan="1" colspan="1">2130–2139</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <named-content content-type="gene" xlink:type="simple">RIQIGTQAIERA</named-content>
                  </td>
                  <td align="left" rowspan="1" colspan="1">2353–2364</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <named-content content-type="gene" xlink:type="simple">RALATNPALRH</named-content>
                  </td>
                  <td align="left" rowspan="1" colspan="1">3888–3898</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <named-content content-type="gene" xlink:type="simple">RQVLFTPATQAARQ</named-content>
                  </td>
                  <td align="left" rowspan="1" colspan="1">4130–4143</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
        </table-wrap>
      </sec>
      <sec id="s2b">
        <title>The UBR4-NS5 interaction correlates with NS5-mediated STAT2 degradation</title>
        <p>UBR4 was found to bind both processed (RFP-ubiquitin-NS5-TAP) (<xref ref-type="fig" rid="ppat-1003265-g001">Figure 1A</xref>), as well as unprocessed NS5 (NS5-HA) (<xref ref-type="fig" rid="ppat-1003265-g001">Figure 1B</xref>). Since cleavage of NS5 promotes STAT2 degradation, we tested whether proteolytic processing would also affect the binding efficiency of NS5 for UBR4. The E domain in <xref ref-type="fig" rid="ppat-1003265-g002">Figure 2A</xref> refers to the E protein of DENV2. Inclusion of a protein (such as E or RFP) upstream of ubiquitin allows one to differentiate between cleaved and uncleaved NS5 <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. HA-tagged unprocessed NS5 (NS5-HA) and processed NS5 (proNS5-HA) (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2A</xref>) were expressed in 293T cells and the NS5 proteins were immunoprecipitated and tested for UBR4 binding. Although both constructs precipitated UBR4, proNS5-HA precipitated two-fold higher amounts of UBR4 than NS5-HA did (as quantified by densitometry) (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2B</xref>).</p>
        <fig id="ppat-1003265-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.ppat.1003265.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>The UBR4-NS5 interaction correlates with NS5-mediated STAT2 degradation.</title>
            <p>(A) A representation of the DENV2 NS5 constructs used in this study. The E domain upstream of ubiquitin refers to the E protein of DENV2. (B and C) HA-tagged DENV NS5 constructs were immunoprecipitated from 293T cells using anti-HA beads. Immunoblot (IB) analysis of the immunoprecipitate (IP) and whole cell extract (WCE) was performed against UBR4, STAT2, HA and β-tubulin or GAPDH. (D) Vero cells expressing HA-tagged DENV NS5 constructs were fixed for immunofluorescence (IF) analysis of UBR4 (green) and NS5 (red). The nuclei were also stained with DAPI (blue). (E) An alignment of the first 10 or 11 amino acids of NS5 from several flaviviruses. Residues that are conserved in all examined flaviviruses are highlighted in green, while those residues that are only conserved amongst the four DENV serotypes are highlighted in red. (F) GFP-tagged DENV2 NS5 constructs and DENV2 NS5 point mutants were immunoprecipitated from 293T cells using anti-GFP antibody and protein G beads. Immunoblot (IB) analysis of the immunoprecipitate (IP) and whole cell extract (WCE) was performed against UBR4, STAT2, GFP and β-tubulin.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003265.g002" position="float" xlink:type="simple"/>
        </fig>
        <p>Given that the first 10 amino acids of NS5 are dispensable for STAT2 binding but indispensable for STAT2 degradation <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>, we asked whether this N terminal region of NS5 was also important for UBR4 binding. To test this, we expressed and immunoprecipitated processed HA-tagged DENV NS5 proteins containing a deletion of 10 or 306 residues at their N-termini, and assessed their ability to bind UBR4. Full length HA-tagged NS5 (NS5-HA) was able to precipitate UBR4 and STAT2, and its ability to precipitate UBR4, but not STAT2, was increased seven-fold (as quantified by densitometry) when DENV NS5 was proteolytically-processed (proNS5-HA) (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2C</xref>). Proteolytically-processed NS5 lacking the first 10 amino acids (proΔ10NS5-HA) precipitated STAT2 but not UBR4, and proteolytically-processed NS5 lacking the first 306 amino acids (proΔ306NS5-HA) precipitated neither protein (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2C</xref>). When protein levels were examined in the whole cell extracts (WCE), STAT2 was reduced in proNS5-HA-expressing cells and slightly reduced in NS5-HA-expressing cells compared with proΔ10NS5-HA- or proΔ306NS5-HA-expressing cells (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2C</xref>), which is consistent with published reports <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. Thus, only the NS5 proteins that bound UBR4 could mediate STAT2 degradation, and increased UBR4 binding by NS5 correlated with increased NS5-mediated STAT2 degradation. The interaction of NS5 with UBR4 and the requirement for the first 10 amino acids of NS5 in mediating this DENV NS5-UBR4 interaction was also observed by NS5-UBR4 colocalization using immunofluorescence analysis in Vero cells (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2D</xref>). To further define which of the N-terminal residues of DENV NS5 are required for its interaction with UBR4, alanine scanning of the first 5 amino acids of DENV NS5 was conducted (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2E</xref>). Immunoprecipitation experiments with these mutant proteins revealed that the threonine (T) at position 2 and the glycine (G) at position 3, which are conserved among the DENV serotypes but absent in other flaviviruses, were required for NS5/UBR4 interaction and NS5-mediated STAT2 degradation (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2F</xref>).</p>
      </sec>
      <sec id="s2c">
        <title>NS5 interaction with UBR4 is independent of STAT2</title>
        <p>The fact that NS5 mutants lacking residues T2 or G3 bound STAT2 but not UBR4 (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2F</xref>) suggested that the interaction between NS5 and UBR4 was independent of STAT2. To confirm this result, the STAT2-deficient U6A cell line <xref ref-type="bibr" rid="ppat.1003265-Leung1">[43]</xref> was transfected with proNS5-HA or proΔ10NS5-HA. ProNS5-HA, but not proΔ10NS5-HA, precipitated UBR4 from U6A cells (<xref ref-type="fig" rid="ppat-1003265-g003">Figure 3A</xref>). Unlike with human STAT2 (hSTAT2), NS5 does not bind and subsequently degrade mouse STAT2 (mSTAT2) <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>. The STAT2 proteins of mouse and human are divergent and share only 70% identity but the UBR4 proteins of mouse and human are 97% identical. When proNS5-HA was expressed in mouse cells (Hepa1.6), mouse UBR4 bound proNS5-HA but not proΔ10NS5-HA confirming that an interaction between NS5 and STAT2 is not required for NS5 to interact with UBR4 (<xref ref-type="fig" rid="ppat-1003265-g003">Figure 3A</xref>). These data suggest that NS5 requires binding to both UBR4 and STAT2 to mediate STAT2 degradation.</p>
        <fig id="ppat-1003265-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.ppat.1003265.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>NS5 promotes STAT2 association with UBR4.</title>
            <p>(A) Proteolytically-processed HA-tagged DENV2 NS5 constructs or an empty vector were expressed in human cells that naturally express human STAT2 (293T cells), human cells that do not express STAT2 (U6A cells), or murine cells that naturally express mouse STAT2 (Hepa1.6), and the lysates of these cells were subjected to anti-HA immunoprecipitation. Immunoblot (IB) analysis of the immunoprecipitate (IP) and whole cell extract (WCE) was performed against UBR4, human STAT2, mouse STAT2, HA and β-tubulin. (B) FLAG-tagged STAT constructs were overexpressed in 293T cells with or without proteolytically-processed HA-tagged DENV2 NS5. Immunoprecipitation was performed against the FLAG epitope, then IB analysis of the IP and WCE was performed against UBR4, FLAG, HA and GAPDH. hSTAT2 = human STAT2; mSTAT2 = mouse STAT2; hSTAT1 = human STAT1; h/mSTAT2 = a chimeric protein with the first 301 amino acids of mouse STAT2 replaced by the corresponding human STAT2 sequence; hSTAT2/1 = a chimeric protein with the first 316 of human STAT1 amino acids replaced by the corresponding human STAT2 sequence. (C) 293T cells and (D) monocyte-derived dendritic cells (MDDC) were mock infected or infected with DENV2 (Thailand/16681 strain) at an MOI of 3 for 24 hours then lysed for IP with anti-STAT2 antibody or control IgG. IB analysis of the IP and WCE was performed against UBR4, UBR5, STAT2, DENV NS5 and β-tubulin.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003265.g003" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s2d">
        <title>Human STAT2 forms a complex with UBR4 in the presence of DENV NS5</title>
        <p>NS5 binds the coiled-coil region located within the first half of hSTAT2 <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>. Though mSTAT2 and human STAT1 (hSTAT1) cannot bind NS5, chimeric proteins that replace the first 301 amino acids of mSTAT2 (h/mSTAT2) or the first 316 amino acids of hSTAT1 (hSTAT2/1) with those of hSTAT2 can bind NS5 <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>. We expressed and immunoprecipitated FLAG-tagged STAT proteins and STAT chimeric proteins in the presence or absence of proNS5-HA. When hSTAT2 was overexpressed, STAT2 degradation was not observed because STAT2 degradation was likely masked by the large amount of overexpressed STAT2 present (<xref ref-type="fig" rid="ppat-1003265-g003">Figure 3B</xref>). However, we observed that while hSTAT1 and mSTAT2 did not bind UBR4, h/mSTAT2, hSTAT2/1 and hSTAT2 all bound UBR4 in the presence of proNS5-HA (<xref ref-type="fig" rid="ppat-1003265-g003">Figure 3B</xref>). Since only those STAT molecules that could bind NS5 could also bind UBR4, and NS5 binds UBR4 in the absence of STAT2, we conclude that NS5 serves as a bridge molecule between STAT2 and UBR4.</p>
        <p>These results were confirmed in the context of DENV infection of a transformed human cell line (293T) and primary untransformed human cells (monocyte-derived dendritic cells or MDDCs) (<xref ref-type="fig" rid="ppat-1003265-g003">Figure 3C and 3D</xref>). Cells were infected with DENV2 at an MOI of 3 for 24 hours, and lysed for immunoprecipitation with STAT2 antibodies or control IgG. Although the majority of STAT2 was degraded during DENV infection, the remaining STAT2 co-immunoprecipitated UBR4 from DENV-infected cells but not from mock-infected cells (<xref ref-type="fig" rid="ppat-1003265-g003">Figure 3C and 3D</xref>), which is consistent with NS5 binding to and bringing together STAT2 and UBR4 during DENV infection.</p>
      </sec>
      <sec id="s2e">
        <title>UBR4 promotes DENV-mediated STAT2 degradation</title>
        <p>We next assessed the functional relevance of UBR4 in DENV-mediated STAT2 degradation. To test if UBR4 is required for DENV-mediated STAT2 degradation, UBR4 levels were stably reduced in 293T cells using small hairpin RNA (shRNA) directed against UBR4. Three stable UBR4-knockdown cell lines were generated using shRNA that targeted different sequences within UBR4. The cells were mock infected or infected with DENV2 at an MOI of 10, and lysed for western blot analysis at 4, 8, 12 and 24 hours post-infection. When cells expressing control non-targeting shRNA were infected with DENV2, STAT2 levels decreased by 4 hours post-infection. However, in the three independently-derived, UBR4-deficient 293T cell lines, STAT2 levels decreased at a slower rate (<xref ref-type="fig" rid="ppat-1003265-g004">Figure 4A</xref>). Furthermore, NS5 levels were lower in the UBR4-knockdown cells than in the control cells suggesting that there was a DENV replication defect in UBR4-knockdown cells. The similar phenotype of the three UBR4-knockdown cell lines and their difference from the control cell line indicated that the effect of UBR4 knockdown on DENV-mediated STAT2 degradation was due to the decreased level of UBR4 and not to off-target effects of the shRNA. We next examined the functional relevance of UBR4 in mediating STAT2 degradation with the other three DENV serotypes (DENV1, 3 or 4). STAT2 levels were higher and NS5 levels were lower in shUBR4-expressing cells than in control cells (<xref ref-type="fig" rid="ppat-1003265-g004">Figure 4B</xref>). Thus, UBR4 is required for efficient STAT2 degradation mediated by all four DENV serotypes.</p>
        <fig id="ppat-1003265-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.ppat.1003265.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>UBR4 promotes DENV-mediated STAT2 degradation.</title>
            <p>(A) 293T cells stably expressing non-targeting shRNA (shControl) or shRNA against UBR4 (shUBR4) were infected with DENV2 (Thailand/16681 strain) at an MOI of 10. Each shUBR4 clone expressed shRNA targeting different sequences within the UBR4 gene. Lysates from mock-infected cells (M) and cells that been infected with DENV2 for 4, 8, 12 or 24 hours were subjected to immunoblot (IB) analysis against UBR4, UBR5, STAT2, DENV NS5 and β-tubulin. (B) Lysates from shControl and shUBR4 293T cells that had been mock infected or infected with DENV1, DENV3 or DENV4 at an MOI of 1 for 24 hours were subjected to IB analysis. (C) A proteolytically-processed HA-tagged DENV NS5 construct or empty vector were transfected into 293T cells stably expressing a V5-tagged construct of the first 2233 amino acids of UBR4 (UBR4-NT). The lysates of these cells were subjected to anti-HA immunoprecipitation. Immunoblot (IB) analysis of the immunoprecipitate (IP) and whole cell extract (WCE) was performed against UBR4, human STAT2, V5, HA and β-tubulin. (D) 293T cells expressing UBR4-NT were mock infected or infected with DENV at an MOI of 1. Lysates were subjected to IB analysis against STAT2, V5, NS5 and β-tubulin at 24 hours post infection.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003265.g004" position="float" xlink:type="simple"/>
        </fig>
        <p>The UBR4 gene is predicted to produce several splice variants encoding proteins of greater than 5000 amino acids. Since it is unclear which UBR4 isoform is required for DENV-mediated STAT2 degradation, we cloned a region of UBR4 (UBR4-NT) that is predicted to be present in all the large UBR4 isoforms and which also contains the UBR box, a 70-amino-acid zinc-finger-like domain required for recognition of N-end rule substrates <xref ref-type="bibr" rid="ppat.1003265-Tasaki1">[42]</xref>. The UBR box is located between amino acids 1662–1723 of the UBR4 reference sequence (NCBI Accession # Q5T4S7), and the UBR4-NT clone encodes amino acids 1–2233 of the reference sequence. Co-immunoprecipitation experiments revealed that proNS5-HA did not bind amino acids 1–2233 of UBR4 (<xref ref-type="fig" rid="ppat-1003265-g004">Figure 4C</xref>) indicating that sequences in the C-terminal half of UBR4 are required to mediate its interaction with NS5. Also, expression of UBR4-NT had no effect on DENV-mediated STAT2 degradation (<xref ref-type="fig" rid="ppat-1003265-g004">Figure 4D</xref>). The experiments in <xref ref-type="fig" rid="ppat-1003265-g004">Figure 4</xref> confirm that a functional UBR4-NS5-STAT2 complex is required for efficient STAT2 degradation and that multiple domains of UBR4 are required for this function.</p>
      </sec>
      <sec id="s2f">
        <title>UBR4 enhances the replication of DENV in an IFN-I-dependent manner</title>
        <p>The ability of DENV to degrade STAT2 determines how well it replicates in an IFN-I-competent cell <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>. Thus, a protein that is required for DENV-mediated STAT2 degradation should also enhance DENV replication in IFN-I-competent cells. To test if UBR4 is required for DENV replication, UBR4-knockdown 293T cells were infected with DENV2 at multiplicities of infection (MOI) of 0.1, 1 and 10, and measured for virus at 24 hours post-infection. DENV replicated to lower levels in UBR4-knockdown cells than in control cells (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5A</xref>). The replication defect was most striking at a lower MOI and an approximately 10-fold decrease in virus levels was observed in shUBR4 cells with an MOI of 0.1 of DENV. In contrast, UBR4 depletion had no effect on the replication of YFV or encephalomyocarditis virus (EMCV), a positive-strand RNA virus belonging to the <italic>Picornaviridae</italic> family, indicating a specific requirement of UBR4 in DENV replication (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5A</xref>). DENV1, 3 and 4 also replicated to lower levels in UBR4-knockdown cells than in control cells indicating that UBR4 is required for the efficient replication of all four DENV serotypes (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5B</xref>).</p>
        <fig id="ppat-1003265-g005" position="float">
          <object-id pub-id-type="doi">10.1371/journal.ppat.1003265.g005</object-id>
          <label>Figure 5</label>
          <caption>
            <title>UBR4 enhances the replication of DENV in an IFN-I-dependent manner.</title>
            <p>(A) 293T cells stably expressing non-targeting shRNA (shControl) or shRNA against UBR4 (shUBR4 #2) were infected with DENV2 (Thailand/16681 strain), YFV (17D strain) or EMCV at the indicated multiplicities of infections (MOI). Cells and media were harvested at 24 hours post-infection and measured for virus by plaque assay on BHK-21 cells. (B) 293T cells were infected with DENV1, 2, 3 or 4 at an MOI of 1 and the virus levels were measured by plaque assay on BHK-21 cells 24 hours later. (C) Vero cells stably expressing non-targeting shRNA (shControl) or shRNA against UBR4 (shUBR4 #1) were infected with DENV2 (Thailand/16681 strain) at an MOI of 0.1. Cells were mock-treated or treated with IFN-I (1000units/ml IFNβ) at 6 hours post infection. Cells and media were harvested at 24 hours post-infection for plaque assay or immunoblotting (IB) with antibodies against UBR4, STAT2, NS5 and β-tubulin. (C) 293T cells were infected with DENV2 at an MOI of 1 and incubated with media containing 0.1 µg/ml control IgG antibody or 0.1 µg/ml IFNAR antibody. Cells and media were harvested at 24 hours post-infection and measured for virus by plaque assay on BHK-21 cells. (D) 293T clones were infected with DENV2 at an MOI = 1 and their RNA harvested at the indicated time post infection. The levels of ISG54 mRNA were measured by qPCR, normalized to 18s (a housekeeping gene) and represented as fold induction over mock samples.). Each graph represents the mean +/− the standard deviation of 6 experiments (A), 3 experiments (B, C and D), or 2 experiments (E). Statistical analyses were conducted using the unpaired t test function of Prism 4 for Macintosh (GraphPad Software, USA). *p&lt;0.05; **p&lt;0.01; *** p&lt;0.001; ns = not statistically significant, where p&gt;0.05.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003265.g005" position="float" xlink:type="simple"/>
        </fig>
        <p>Since UBR4 was required for DENV-mediated STAT2 degradation, we hypothesized that the DENV replication defect in UBR4-deficient cells was due to an inability of DENV to antagonize IFN-I signaling by degrading STAT2. If this is the case, lack of IFN-I should compensate for the requirement of UBR4 in DENV replication. To test this, we infected control and UBR4-knockdown Vero cells with DENV. Vero cells lack IFN-I genes and therefore cannot make IFN-I in response to viral infection <xref ref-type="bibr" rid="ppat.1003265-Emeny1">[45]</xref>. DENV replicated to similar levels in UBR4-knockdown and control Vero cells (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5C</xref>). Yet when Vero cells were infected with DENV and then exogenously treated with IFN-I 6 hours later, a DENV replication defect was observed in the UBR4-deficient Vero cells (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5C</xref>). Protein levels of NS5, UBR4, and STAT2 in UBR4-knockdown Vero cells showed that UBR4 levels were indeed lower and that DENV-mediated STAT2 degradation was defective in UBR4-knockdown cells (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5B</xref>).</p>
        <p>Treating DENV-infected UBR4-knockdown 293T cells with a neutralizing anti-IFNAR antibody corroborated the effect of IFN-I on DENV replication in UBR4-deficient Vero cells (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5D</xref>). We observed a significant increase in DENV replication in UBR4-knockdown 293T cells treated with the neutralizing anti-IFNAR antibody compared to UBR4-knockdown 293T cells treated with IgG control antibodies. This contrasts with what was observed in control 293T cells where DENV replication was unaffected by treatment with anti-IFNAR antibodies (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5D</xref>).</p>
        <p>IFN exerts its biological effect by upregulating interferon-stimulated genes (ISGs), which encode products that restrict viral replication. To examine the biological relevance of UBR4 in preventing the antiviral action of IFN-I during DENV infection, we examined the induction of ISG54 mRNA in UBR4-knockdown 293T cells. There was a significant induction of ISG54 mRNA in UBR4-knockdown cells during DENV infection compared to control cells (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5E</xref>). These results indicate that UBR4 is required for preventing the antiviral action of IFN-I during DENV infection.</p>
        <p>Dendritic cells are thought to be an important cell type in which DENV replicates <italic>in vivo</italic> <xref ref-type="bibr" rid="ppat.1003265-Jessie1">[46]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Kou1">[47]</xref>. We reduced UBR4 levels in primary MDDCs from five donors using shRNA lentiviral constructs, and tested the effect of this decrease on DENV replication. When MDDCs from each donor were infected at an MOI of 3, approximately 35% of transfected cells were highly infected and showed viral glycoprotein (E) expression by FACS. At 12 hours post infection, as expected, the levels of UBR4 were decreased in the UBR4-knockdown cells compared to control cells (<xref ref-type="fig" rid="ppat-1003265-g006">Figure 6A</xref>). When the levels of ISG15, RIG-I and ISG54 mRNA were analyzed in these cells, more ISGs were induced in four of the five donors (<xref ref-type="fig" rid="ppat-1003265-g006">Figure 6B, 6C and 6D</xref> respectively). In addition, more DENV was present in control cells than in UBR4-knockdown cells at 48 hours post infection (<xref ref-type="fig" rid="ppat-1003265-g006">Figure 6E</xref>). Thus, UBR4 is required for inhibiting ISG induction and increasing DENV replication in a primary cell type that is of importance in DENV infections.</p>
        <fig id="ppat-1003265-g006" position="float">
          <object-id pub-id-type="doi">10.1371/journal.ppat.1003265.g006</object-id>
          <label>Figure 6</label>
          <caption>
            <title>UBR4 enhances the replication of DENV in monocyte-derived dendritic cells.</title>
            <p>Monocytes from 5 donors were transduced with a non-targeting shRNA lentivirus (shControl) or an shRNA lentivirus against UBR4 (shUBR4 #2). Monocytes were differentiated for 5 days to monocyte-derived dendritic cells (MDDCs) before infecting with DENV2 (Thailand/16681 strain) at an MOI of 3. Cells were harvested at 12 hours post infection for measurement of (A) UBR4, (B) ISG15, (C) RIG-I, and (D) ISG54 mRNA levels, or (E) supernatants were harvested at 48 hours post infection for measurement of virus levels via plaque assay. RIG-I mRNA was undetectable in 1 donor. Statistical analyses were conducted using the two-way ANOVA function of Prism 4 for Macintosh (GraphPad Software, USA). p&lt;0.001 for UBR4, ISG15, RIG-I and ISG54 levels and p&lt;0.01 for DENV titers in shControl versus shUBR4 cells.</p>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003265.g006" position="float" xlink:type="simple"/>
        </fig>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>The IFN-I response is one of the first lines of protection against DENV infection, and serves to curb viral replication and dissemination by generating an antiviral intracellular environment <xref ref-type="bibr" rid="ppat.1003265-Diamond1">[48]</xref>. The potency of the type I IFN pathway is exemplified by the fact that DENV antagonizes both IFN synthesis and IFN signaling in order to ensure its replication and survival <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Mazzon1">[14]</xref>, <xref ref-type="bibr" rid="ppat.1003265-RodriguezMadoz1">[33]</xref>, <xref ref-type="bibr" rid="ppat.1003265-RodriguezMadoz2">[34]</xref>, <xref ref-type="bibr" rid="ppat.1003265-MunozJordan1">[35]</xref>, <xref ref-type="bibr" rid="ppat.1003265-MunozJordan2">[36]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Jones1">[37]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Ho1">[38]</xref>. DENV NS5 inhibits IFN-I signaling by mediating proteasome-dependent STAT2 degradation, and STAT2 degradation promotes DENV replication <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Mazzon1">[14]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>. With this study, we report the discovery of a host factor, UBR4, that is essential for DENV-dependent STAT2 degradation. We describe the interaction of UBR4 with NS5 and show that this interaction is crucial for inhibiting type-I IFN signaling and promoting efficient DENV replication.</p>
      <p>UBR4 associates with DENV NS5 but not with the closely related YFV NS5 or WNV NS5. UBR4 also binds preferentially to proteolytically-processed DENV NS5, which is the form of NS5 that efficiently mediates STAT2 degradation. Binding of UBR4 to DENV NS5 requires amino acids T2 and G3 of NS5, which are also critical for STAT2 degradation. These amino acids are conserved amongst the four DENV serotypes but are absent in other flaviviruses (<xref ref-type="fig" rid="ppat-1003265-g002">Figure 2F</xref>). Though NS5 is the most highly conserved flavivirus protein, the high degree of specificity exhibited by UBR4 for DENV NS5 underscores the differences between the various flaviviral NS5 proteins.</p>
      <p>In 293T cells and primary human dendritic cells, DENV replicates best when UBR4 levels are normal, but when UBR4 levels are reduced, DENV-mediated STAT2 degradation is reduced and DENV replication decreases as a consequence (<xref ref-type="fig" rid="ppat-1003265-g005">Figures 5</xref> and <xref ref-type="fig" rid="ppat-1003265-g006">6</xref>). In Vero cells, which do not produce IFN-I <xref ref-type="bibr" rid="ppat.1003265-Emeny1">[45]</xref>, UBR4 depletion does not affect DENV replication unless these cells are treated with exogenous IFN-I (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5C</xref>). Furthermore, the DENV replication defect caused by UBR4 knockdown in 293T cells can be decreased by treating the cells with antibodies that block the IFN-I receptor and decrease IFN-I signaling (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5D</xref>). The DENV replication defect seen in UBR4-knockdown 293Ts and MDDCs can be explained by an increase in ISG levels in DENV-infected UBR4-knockdown cells versus DENV-infected control cells (<xref ref-type="fig" rid="ppat-1003265-g005">Figure 5E</xref> and <xref ref-type="fig" rid="ppat-1003265-g006">Figure 6</xref>). Thus, in the absence of IFN-I, there is no need for DENV to antagonize IFN-I signaling and cellular levels of UBR4 are irrelevant for DENV replication. However, upon activation of the IFN-I signaling pathway, UBR4 becomes necessary for DENV replication. Reducing STAT2 levels is essential for DENV to preempt the establishment of a cellular antiviral state, thus ensuring its efficient replication.</p>
      <p>Antagonism of IFN signaling is one of the factors responsible for the limited host tropism of DENV to human and nonhuman primates. DENV does not replicate to high levels or induce disease in IFN-competent mice <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Perry1">[49]</xref>. Our previous results indicated that the cellular machinery needed for DENV replication in murine cells is in place but is limited by the inability of NS5 to associate with murine STAT2 and inhibit murine IFN-I signaling <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>. Other blocks such as the type II IFN pathway also diminish DENV replication in mice, but the IFN-I signaling pathway restricts early replication <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Shresta1">[50]</xref>. Here we show that DENV NS5 associates with murine UBR4 in murine cells. This is in keeping with our previous results <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>, and suggests that the development of a genetically-modified mouse that expresses a functional human STAT2 in place of its murine counterpart should allow increased DENV replication. We predict, therefore, that DENV NS5 will mediate human STAT2 degradation in these mice by co-opting mouse UBR4. Such a mouse might provide the basis for the development of an immune-competent mouse model of DENV infections.</p>
      <p>The 600 kDa large UBR4 is highly conserved and found in organisms as diverse as mammals, insects, plants and worms. It belongs to the N-recognin family, which contains proven and predicted E3 ligases that recognize and degrade proteins containing destabilizing N termini. The seven members of the UBR family, UBR1 to UBR7, encode a 70-amino-acid zinc finger motif known as the UBR box, which is necessary for substrate recognition <xref ref-type="bibr" rid="ppat.1003265-Tasaki1">[42]</xref>. The better-characterized members of the UBR family are UBR1, UBR2 and UBR5. UBR1 and UBR2 are RING domain-containing N-recognins, which recognize N-end rule substrates and target them for degradation <xref ref-type="bibr" rid="ppat.1003265-Tasaki1">[42]</xref>. UBR1 and UBR2 are also involved in N-end-rule-independent quality control protein degradation <xref ref-type="bibr" rid="ppat.1003265-Sultana1">[51]</xref>. UBR5 is a HECT-domain containing E3 ligase that binds N-end rule substrates <xref ref-type="bibr" rid="ppat.1003265-Tasaki1">[42]</xref>, but can also target non-N-end rule substrates like E6AP for degradation <xref ref-type="bibr" rid="ppat.1003265-Tomaic1">[52]</xref>. UBR4 contains neither a HECT nor a RING domain.</p>
      <p>A dearth of UBR4 literature exists because of the difficulty that manipulating the UBR4 gene presents. The UBR4 gene contains 106 exons, and produces multiple splice variants that conceivably have different functions. UBR4 forms a chromatin scaffold when bound to retinoblastoma protein (Rb) in the nucleus, and it also influences cytoskeleton organization by binding clathrin in the cytoplasm <xref ref-type="bibr" rid="ppat.1003265-Nakatani1">[53]</xref>. Both of these are structural roles for which no N-end rule or other E3 ligase activities have been detected. A second virus, human papilloma virus, is known to exploit UBR4's role in cellular morphology to initiate anchorage-independent growth and cellular transformation <xref ref-type="bibr" rid="ppat.1003265-DeMasi1">[54]</xref>, <xref ref-type="bibr" rid="ppat.1003265-Huh1">[55]</xref>. Although UBR4 is part of a family of UBR E3 ligases involved in the N-end rule pathway, the involvement of the N-end rule in the NS5-dependent degradation of STAT2 seems unlikely. Our group has previously demonstrated that the identity of NS5's first residue is not relevant for STAT2 degradation as long as the precursor is correctly processed <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. In addition, we show that residues T2 and G3 of NS5 are critical for binding to UBR4 and for mediating STAT2 degradation, but they are considered to be stabilizing residues within the N-end rule. This does not exclude UBR4 from having E3 ligase activity that is independent of the N-end rule. Though it lacks an obvious catalytic domain such as the HECT or RING domains, UBR4 contains a cysteine-rich domain (CRD) that is unique to the UBR4 group. It is currently unknown if CRD functions as a ligase domain. Our experiments with the N-terminal region of UBR4 suggest that domains from the C terminus, which contain the CRD, are necessary for its function in DENV-mediated STAT2 degradation.</p>
      <p>Finally, we propose two working models: one based on the hypothesized UBR4 E3 ligase catalytic activity, and another which postulates a scaffolding role for UBR4 based on its described interactions with clathrin and retinoblastoma protein (<xref ref-type="fig" rid="ppat-1003265-g007">Figure 7</xref>). Efforts are currently being made to clone and express the predicted UBR4 isoforms so as to further evaluate the function of UBR4 in DENV-mediated STAT2 degradation, and to explore its potential as a target for rationally-designed DENV therapeutics.</p>
      <fig id="ppat-1003265-g007" position="float">
        <object-id pub-id-type="doi">10.1371/journal.ppat.1003265.g007</object-id>
        <label>Figure 7</label>
        <caption>
          <title>Model of DENV-mediated STAT2 degradation.</title>
          <p>NS2B/3 protease cleaves NS4B away from NS5 to yield proteolytically-processed NS5. Proteolytically-processed NS5 brings STAT2 into contact with the degradation machinery of the cell by binding UBR4. UBR4 may function as an E3 ligase (A), but as it lacks a known E3 ligase catalytic domain such as the HECT or RING, it may instead act as the recognition component or scaffold of an E3 ligase complex (B). STAT2 degradation prevents the establishment of an antiviral state thereby allowing DENV to replicate optimally.</p>
        </caption>
        <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.ppat.1003265.g007" position="float" xlink:type="simple"/>
      </fig>
    </sec>
    <sec id="s4" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s4a">
        <title>Cell lines and viruses</title>
        <p>293T, Hepa1.6, U6A, BHK and Vero cells were maintained in DMEM (Life Technologies) supplemented with 10% fetal bovine serum (Life Technologies) and 1% penicillin/streptomycin mix (Life Technologies). C6/36 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (Life Technologies). Hepa1.6 cells were kindly provided by Matthew Evans (Mount Sinai School of Medicine, New York, NY). U6A cells were a kind gift of George Stark (Lerner Research Institute, Cleveland, OH) and were previously described <xref ref-type="bibr" rid="ppat.1003265-Leung1">[43]</xref>.</p>
        <p>High-titer stocks of DENV1, DENV2, DENV3, DENV4, yellow fever virus (YFV-17D) and encephalomyocarditis virus (EMCV) were obtained by passage in C6/36 cells, BHK cells, and Vero cells, respectively.</p>
      </sec>
      <sec id="s4b">
        <title>Plasmids and transfections</title>
        <p>pCAGGS-CTAP was a kind gift from Luis Martinez-Sobrido (University of Rochester). A gene cloned into pCAGGS-CTAP produces a fusion protein that is C-terminally tagged with a TAP tag: calmodulin binding protein followed by two tobacco etch virus (TEV) cleavage sites followed by a protein A tag. The sequences of the primers used for the construction of the RFP-ubiquitin-NS5 fragment that was cloned into pCAGGS-CTAP are available upon request. The primers sequences used for cloning UBR4-NT (1–2233 of UBR4, NCBI Accession Q5T4S7) into pCDNA6 are also available upon request. All other viral gene expression constructs were cloned into pCAGGS-HA and were described previously <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>, <xref ref-type="bibr" rid="ppat.1003265-LaurentRolle1">[15]</xref>. The Flag-tagged STAT1, STAT2 and chimeric STAT constructs were previously described <xref ref-type="bibr" rid="ppat.1003265-Ashour2">[44]</xref>.</p>
        <p>All cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. 293T cells were transfected at a ratio 1∶2 (µg plasmid DNA: µL Lipofectamine 2000) while Vero, Hepa1.6 and U6A cells were transfected at a ratio 1∶3.</p>
      </sec>
      <sec id="s4c">
        <title>Tandem affinity purification and immunoprecipitation</title>
        <p>Cells were lysed for tandem affinity purification (TAP) or immunoprecipitation two days post transfection. For tandem affinity purification, cells were lysed in TAP buffer (25% glycerol, 50 mM Tris HCL pH 8, 0.5% NP40, 200 mM NaCl, 1 mM β-mercaptoethanol, protease inhibitor cocktail (Roche). Lysates were spun at 15,000 g for 10 minutes and the supernatant was incubated with IgG beads (Roche) for 4 hours then washed with TAP buffer. The beads were then incubated with TEV buffer (TAP buffer containing 0.5 mM EDTA, 1 mM DTT units) and 50 units AcTEV enzyme (Invitrogen) overnight. The beads were spun at 15,000 g for 10 minutes then the supernatant was applied to calmodulin beads (Roche) in a calmodulin bead (CB) buffer (TAP buffer containing 4 mM CaCl<sub>2</sub> and 2 mM imidazole) for 8 hours, then washed in CB buffer. The protein was eluted from the calmodulin beads by boiling for five minutes in Laemmli sample buffer (BioRad).</p>
        <p>For immunoprecipitation, cells were lysed in TAP buffer then incubated for two hours with anti-FLAG or anti-HA beads (#F2426 and #E6779 respectively, Sigma-Aldrich) or for 4 hours with rabbit anti-STAT2 antibody (Santa Cruz) or mouse anti-GFP antibody (Abcam) followed by 2 hours of protein A-agarose (Roche) or protein G-agarose (Roche), respectively. The beads were washed with TAP buffer then the protein was eluted from the beads by boiling for five minutes in Laemmli sample buffer (BioRad).</p>
      </sec>
      <sec id="s4d">
        <title>Western blot analysis of transfected and infected cells</title>
        <p>Proteins lysates were boiled with Laemmli sample buffer and resolved on 4–15% or 7.5% gels (BioRad) and then transferred to PVDF membrane (Millipore) by standard methods. Membranes were blocked with 3% BSA in TBS-Tween (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1% Tween) and then incubated with antibodies and subjected to western blot. Benchmark Protein Ladder (Invitrogen) was used to depict the size of protein bands. The primary antibodies used in this study were: rabbit anti-human STAT2 (sc-476, Santa Cruz), rabbit anti-mouse STAT2 (4597, Cell Signaling), rabbit anti-STAT1 (610120, BD Biosciences), mouse anti-β-tubulin (T0198, Sigma-Aldrich), mouse anti-HA (H9658, Sigma-Aldrich), mouse anti-Flag (F3165, Sigma-Aldrich), mouse anti-V5 (R960-25, Invitrogen), rabbit anti-UBR4 (ab86738, Abcam), HRP-linked anti-GAPDH (ab9385, Abcam), rabbit anti-UBR5 (ab70311, Abcam), and rabbit anti-NS5 <xref ref-type="bibr" rid="ppat.1003265-Ashour1">[13]</xref>. The secondary antibodies used in this study were HRP-linked anti-mouse IgG (#NA931V, GE Healthcare) and HRP-linked anti-rabbit IgG (#NA934V, GE Healthcare). Where indicated, quantification of western blots was done by using Image J to compare the ratio of UBR4 (seen as two bands or one band based on the resolution of the tris-glycine gel used) to NS5.</p>
      </sec>
      <sec id="s4e">
        <title>Immunofluorescence</title>
        <p>To analyze the intracellular localization of endogenous UBR4 and DENV NS5, Vero cells that had been grown on glass cover slips were transfected with 1 µg of the indicated plasmids. After 24 hours post infection, cells were fixed and permeabilized for 30 minutes with ice cold methanol acetone (1∶1, v/v) and 0.5% NP-40, then washed with PBS. Following PBS washes, cells were blocked in blocking buffer (0.2% cold waterfish gelatin (Sigma-Aldrich, USA) and 0.5% BSA in PBS) for 1 hour at room temperature (RT), and stained with primary antibodies (anti-UBR4 at a 1∶100 dilution, and anti-HA at a 1∶1000 dilution) overnight at 4°C. The cells were washed in PBS and incubated with secondary antibodies to Alexa Fluor 488 and Alexa Fluor 555 (Invitrogen, USA) at 1∶500 dilution in blocking buffer for 1 hour at RT. Nuclear chromatin staining was performed by incubation in blocking solution containing 0.5 mg/ml 4′,6-diamidino-2-phenylindole, DAPI (Sigma-Aldrich). Cells were washed and coverslips mounted using Prolong antifade reagent (Invitrogen). Images were captured using a Leica SP5-DM confocal microscope at the Microscopy Shared Research Facility at Mount Sinai School of Medicine.</p>
      </sec>
      <sec id="s4f">
        <title>Establishment of knockdown cell lines with lentiviruses expressing shRNA</title>
        <p>The 293T and Vero cell lines stably expressing non-silencing shRNA or shRNA against UBR4 were made by infecting cells with shRNA-encoding lentiviruses (according to the manufacturer's protocol) and selecting cells with puromycin (1 µg/ml for 293T cells and 5 µg/ml for Vero cells) for two weeks before DENV, YFV or EMCV infection.</p>
        <p>The lentiviruses used to make 293T shUBR4 clones were purchased from Open Biosystems. Lentivirus 1 (Clone ID: V3LHS_318553; target sequence: <named-content content-type="gene" xlink:type="simple">CGCTTCGACTTCATGCTCT</named-content>) targets nucleotides 11132–11150 of UBR4. Lentivirus 2 (Catalog #: V3LHS_318554; target sequence: <named-content content-type="gene" xlink:type="simple">CGGATCAGCTCCTATGTCA</named-content>) targets nucleotides 3140–3158 of UBR4. Lentivirus 3 (Catalog #: V3LHS_318555; target sequence: <named-content content-type="gene" xlink:type="simple">AGGTTTTTGTCTACAATGA</named-content>) targets nucleotides 2357–2375 of UBR4. The non-silencing control lentivirus was catalog number RHS4348. The Vero shUBR4 clone was made using lentivirus 1, while the Vero shControl was made using non-silencing control lentivirus.</p>
      </sec>
      <sec id="s4g">
        <title>Infection of 293T and Vero cells</title>
        <p>Cells were infected at the indicated multiplicity of infection (MOI) and maintained in DMEM with 10% FBS. For exogenous IFN-I treatment of Vero cells, 1000 units/ml IFNβ (PBL Interferon Source) were added at 6 hours post infection. For western blotting, cells were lysed with TAP buffer at each time point and the lysates were clarified by centrifugation then boiled in Laemmli sample buffer. For virus titration, cells and media were frozen at each time point and clarified by centrifugation. DENV and YFV titers were measured by plaque assay on BHK-21 cells, and EMCV titers were measured by plaque assay on Vero cells.</p>
      </sec>
      <sec id="s4h">
        <title>Isolation, transduction and stimulation of MDDCs</title>
        <p>Peripheral blood mononuclear cells were isolated from buffy coats of healthy human donors by Ficoll density gradient centrifugation (Histopaque, Sigma Aldrich) as previously described <xref ref-type="bibr" rid="ppat.1003265-RodriguezMadoz1">[33]</xref>. Buffy coats were obtained from the Mount Sinai Blood Donor Center and New York Blood Center. Briefly, CD14+ cells were purified using anti-human CD14 antibody-labeled magnetic beads and iron-based MiniMACS LS columns (Miltenyi Biotech). After elution from the columns, 2×10<sup>5</sup> cells were plated in 96-well plates and transduced with VSV-G pseudo-typed SIV VLPs (pSIV3+, an SIV gag-pol expression plasmid containing Vpx) and lentiviral control or UBR4-specific shRNA vectors for 3 hours by spinoculation in the presence of 2 µg/mL polybrene (Sigma) with sufficient viruses to transduce &gt;95% of the cells. Subsequently, cells were washed, resuspended in DC medium (RPMI medium [Invitrogen], 10% fetal calf serum [HyClone], 100 U/ml penicillin, and 100 µg/ml streptomycin [Invitrogen]) supplemented with 500 U/ml human granulocyte-macrophage colony-stimulating (Peprotech), and 1,000 U/ml human interleukin-4 (hIL-4; Peprotech), and incubated for 5 days at 37°C. At 5 days post transduction, MDDCs were either mock infected or infected with DENV2 at an MOI of 3. At 12 hours post infection (hpi) cells were harvested for qPCR analysis, and at 48 hpi supernatants were collected for titration of virus levels by plaque assay on BHK-21 cells. Cells were also harvested for cytometry analysis.</p>
      </sec>
      <sec id="s4i">
        <title>Quantitative RT-PCR (qPCR)</title>
        <p>Total RNA was isolated from samples using the RNeasy kit (Qiagen) and subjected to DNase digestion with Turbo DNase (Ambion). Reverse transcription was performed using the high capacity cDNA reverse transcription kit (Applied Biosystems). qPCR was performed in 384-well plates in triplicates using SYBR green I master mix (Roche) in a Roche LightCycler 480. Relative mRNA values were calculated using the ΔΔCt method using 18S rRNA as internal control and plotted as fold change by normalizing to mock-control samples.</p>
        <p>UBR4 qPCR primers: Forward = <named-content content-type="gene" xlink:type="simple">GGTGTTCCAGAGGCTAGTGATC</named-content>; Reverse = <named-content content-type="gene" xlink:type="simple">CCAACTGCTTCTGCGGTTCCTT</named-content></p>
        <p>ISG15 qPCR primers: Forward = <named-content content-type="gene" xlink:type="simple">TCCTGGTGAGGAATAACAAGGG</named-content>; Reverse = <named-content content-type="gene" xlink:type="simple">GTCAGCCAGAACAGGTCGTC</named-content></p>
        <p>RIG-I qPCR primers: Forward = <named-content content-type="gene" xlink:type="simple">GGCATGTTACACAGCTGACG</named-content>; Reverse = <named-content content-type="gene" xlink:type="simple">TGCAATATCCTCCACCACAA</named-content></p>
        <p>ISG54 qPCR primers: Forward = <named-content content-type="gene" xlink:type="simple">ATGTGCAACCTACTGGCCTAT</named-content>; Reverse = <named-content content-type="gene" xlink:type="simple">TGAGAGTCGGCCCATGTGATA</named-content></p>
        <p>18S RNA qPCR primers: Forward = <named-content content-type="gene" xlink:type="simple">GTAACCCGTTGAACCCCATT</named-content>; Reverse = <named-content content-type="gene" xlink:type="simple">CCATCCAATCGGTAGTAGCG</named-content></p>
      </sec>
      <sec id="s4j">
        <title>Flow cytometry</title>
        <p>DENV-infected DCs were fixed and permeabilized with Cytofix and Cytoperm reagent (BD Pharmingen) according to the manufacturer's recommendations. Then, cells were stained with 4G2 (ATCC), a mouse monoclonal antibody specific for the E protein, as a primary antibody and a FITC-labeled anti-mouse antibody as a secondary antibody. Flow cytometry was performed using a FACScan flow cytometer (Becton Dickinson) and analyzed with FlowJo software.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Dabeiba Bernal-Rubio for excellent technical assistance. Confocal microscopy was performed at the Mount Sinai School of Medicine Microscopy Shared Resource Facility.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="ppat.1003265-Chen1">
        <label>1</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vasilakis</surname><given-names>N</given-names></name> (<year>2011</year>) <article-title>Dengue–quo tu et quo vadis?</article-title> <source>Viruses</source> <volume>3</volume>: <fpage>1562</fpage>–<lpage>1608</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Rice1">
        <label>2</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Lenches</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Eddy</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Sheets</surname><given-names>RL</given-names></name>, <etal>et al</etal>. (<year>1985</year>) <article-title>Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution</article-title>. <source>Science</source> <volume>229</volume>: <fpage>726</fpage>–<lpage>733</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Coia1">
        <label>3</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Coia</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Parker</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Speight</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Byrne</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Westaway</surname><given-names>EG</given-names></name> (<year>1988</year>) <article-title>Nucleotide and complete amino acid sequences of Kunjin virus: definitive gene order and characteristics of the virus-specified proteins</article-title>. <source>J Gen Virol</source> <volume>69</volume> (<issue>Pt 1</issue>) <fpage>1</fpage>–<lpage>21</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Lindenbach1">
        <label>4</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lindenbach</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name> (<year>2003</year>) <article-title>Molecular biology of flaviviruses</article-title>. <source>Adv Virus Res</source> <volume>59</volume>: <fpage>23</fpage>–<lpage>61</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Chu1">
        <label>5</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chu</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Westaway</surname><given-names>EG</given-names></name> (<year>1987</year>) <article-title>Characterization of Kunjin virus RNA-dependent RNA polymerase: reinitiation of synthesis in vitro</article-title>. <source>Virology</source> <volume>157</volume>: <fpage>330</fpage>–<lpage>337</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Egloff1">
        <label>6</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egloff</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Benarroch</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Selisko</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Romette</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Canard</surname><given-names>B</given-names></name> (<year>2002</year>) <article-title>An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization</article-title>. <source>EMBO J</source> <volume>21</volume>: <fpage>2757</fpage>–<lpage>2768</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Zhou1">
        <label>7</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ray</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Structure and function of flavivirus NS5 methyltransferase</article-title>. <source>J Virol</source> <volume>81</volume>: <fpage>3891</fpage>–<lpage>3903</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Issur1">
        <label>8</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Issur</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Geiss</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Bougie</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Picard-Jean</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Despins</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure</article-title>. <source>RNA</source> <volume>15</volume>: <fpage>2340</fpage>–<lpage>2350</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Daffis1">
        <label>9</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Daffis</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Szretter</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Schriewer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Youn</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members</article-title>. <source>Nature</source> <volume>468</volume>: <fpage>452</fpage>–<lpage>456</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Best1">
        <label>10</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Best</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Shannon</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Robertson</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Mitzel</surname><given-names>DN</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist</article-title>. <source>J Virol</source> <volume>79</volume>: <fpage>12828</fpage>–<lpage>12839</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Lin1">
        <label>11</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>YL</given-names></name> (<year>2006</year>) <article-title>Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism</article-title>. <source>J Virol</source> <volume>80</volume>: <fpage>5908</fpage>–<lpage>5918</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Werme1">
        <label>12</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Werme</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wigerius</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Johansson</surname><given-names>M</given-names></name> (<year>2008</year>) <article-title>Tick-borne encephalitis virus NS5 associates with membrane protein scribble and impairs interferon-stimulated JAK-STAT signalling</article-title>. <source>Cell Microbiol</source> <volume>10</volume>: <fpage>696</fpage>–<lpage>712</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Ashour1">
        <label>13</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ashour</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Laurent-Rolle</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>PY</given-names></name>, <name name-style="western"><surname>Garcia-Sastre</surname><given-names>A</given-names></name> (<year>2009</year>) <article-title>NS5 of dengue virus mediates STAT2 binding and degradation</article-title>. <source>J Virol</source> <volume>83</volume>: <fpage>5408</fpage>–<lpage>5418</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Mazzon1">
        <label>14</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mazzon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Davidson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chain</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>M</given-names></name> (<year>2009</year>) <article-title>Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation</article-title>. <source>J Infect Dis</source> <volume>200</volume>: <fpage>1261</fpage>–<lpage>1270</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-LaurentRolle1">
        <label>15</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Laurent-Rolle</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Boer</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Lubick</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Wolfinbarger</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Carmody</surname><given-names>AB</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling</article-title>. <source>J Virol</source> <volume>84</volume>: <fpage>3503</fpage>–<lpage>3515</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Morrison1">
        <label>16</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morrison</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aguirre</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fernandez-Sesma</surname><given-names>A</given-names></name> (<year>2012</year>) <article-title>Innate immunity evasion by dengue virus</article-title>. <source>Viruses</source> <volume>4</volume>: <fpage>397</fpage>–<lpage>413</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Li1">
        <label>17</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Labrecque</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gauzzi</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Cuddihy</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>AH</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha</article-title>. <source>Oncogene</source> <volume>18</volume>: <fpage>5727</fpage>–<lpage>5737</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Miller1">
        <label>18</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Miller</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rahill</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Waldman</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Sedmak</surname><given-names>DD</given-names></name> (<year>1999</year>) <article-title>Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction</article-title>. <source>J Immunol</source> <volume>162</volume>: <fpage>6107</fpage>–<lpage>6113</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Parisien1">
        <label>19</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parisien</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Moscona</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2</article-title>. <source>Virology</source> <volume>283</volume>: <fpage>230</fpage>–<lpage>239</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Parisien2">
        <label>20</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parisien</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Rodriguez</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Ulane</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>CM</given-names></name> (<year>2002</year>) <article-title>Selective STAT protein degradation induced by paramyxoviruses requires both STAT1 and STAT2 but is independent of alpha/beta interferon signal transduction</article-title>. <source>J Virol</source> <volume>76</volume>: <fpage>4190</fpage>–<lpage>4198</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Vidy1">
        <label>21</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vidy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chelbi-Alix</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Blondel</surname><given-names>D</given-names></name> (<year>2005</year>) <article-title>Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways</article-title>. <source>J Virol</source> <volume>79</volume>: <fpage>14411</fpage>–<lpage>14420</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Mackenzie1">
        <label>22</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mackenzie</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Khromykh</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Parton</surname><given-names>RG</given-names></name> (<year>2007</year>) <article-title>Cholesterol manipulation by West Nile virus perturbs the cellular immune response</article-title>. <source>Cell Host Microbe</source> <volume>2</volume>: <fpage>229</fpage>–<lpage>239</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Morrison2">
        <label>23</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morrison</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Racaniello</surname><given-names>VR</given-names></name> (<year>2009</year>) <article-title>Proteinase 2Apro is essential for enterovirus replication in type I interferon-treated cells</article-title>. <source>J Virol</source> <volume>83</volume>: <fpage>4412</fpage>–<lpage>4422</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Valmas1">
        <label>24</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Valmas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Grosch</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Schumann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Olejnik</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>O</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Marburg virus evades interferon responses by a mechanism distinct from Ebola virus</article-title>. <source>PLoS Pathog</source> <volume>6</volume>: <fpage>e1000721</fpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Hollidge1">
        <label>25</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hollidge</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Soldan</surname><given-names>SS</given-names></name> (<year>2011</year>) <article-title>The role of interferon antagonist, non-structural proteins in the pathogenesis and emergence of arboviruses</article-title>. <source>Viruses</source> <volume>3</volume>: <fpage>629</fpage>–<lpage>658</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Thompson1">
        <label>26</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thompson</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Kaminski</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Kurt-Jones</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname><given-names>KA</given-names></name> (<year>2011</year>) <article-title>Pattern recognition receptors and the innate immune response to viral infection</article-title>. <source>Viruses</source> <volume>3</volume>: <fpage>920</fpage>–<lpage>940</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Stark1">
        <label>27</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stark</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Darnell</surname><given-names>JE</given-names><suffix>Jr</suffix></name> (<year>2012</year>) <article-title>The JAK-STAT pathway at twenty</article-title>. <source>Immunity</source> <volume>36</volume>: <fpage>503</fpage>–<lpage>514</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Schindler1">
        <label>28</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schindler</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Decker</surname><given-names>T</given-names></name> (<year>2007</year>) <article-title>JAK-STAT signaling: from interferons to cytokines</article-title>. <source>J Biol Chem</source> <volume>282</volume>: <fpage>20059</fpage>–<lpage>20063</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Der1">
        <label>29</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Der</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Silverman</surname><given-names>RH</given-names></name> (<year>1998</year>) <article-title>Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>95</volume>: <fpage>15623</fpage>–<lpage>15628</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-deVeer1">
        <label>30</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Veer</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Holko</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Frevel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Der</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Functional classification of interferon-stimulated genes identified using microarrays</article-title>. <source>J Leukoc Biol</source> <volume>69</volume>: <fpage>912</fpage>–<lpage>920</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Schoggins1">
        <label>31</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schoggins</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Panis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>CT</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>A diverse range of gene products are effectors of the type I interferon antiviral response</article-title>. <source>Nature</source> <volume>472</volume>: <fpage>481</fpage>–<lpage>485</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Schoggins2">
        <label>32</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schoggins</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name> (<year>2012</year>) <article-title>Interferon-stimulated genes and their antiviral effector functions</article-title>. <source>Curr Opin Virol</source> <volume>1</volume>: <fpage>519</fpage>–<lpage>525</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-RodriguezMadoz1">
        <label>33</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rodriguez-Madoz</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Belicha-Villanueva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bernal-Rubio</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ashour</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ayllon</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex</article-title>. <source>J Virol</source> <volume>84</volume>: <fpage>9760</fpage>–<lpage>9774</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-RodriguezMadoz2">
        <label>34</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rodriguez-Madoz</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Bernal-Rubio</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kaminski</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fernandez-Sesma</surname><given-names>A</given-names></name> (<year>2010</year>) <article-title>Dengue virus inhibits the production of type I interferon in primary human dendritic cells</article-title>. <source>J Virol</source> <volume>84</volume>: <fpage>4845</fpage>–<lpage>4850</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-MunozJordan1">
        <label>35</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Munoz-Jordan</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Sanchez-Burgos</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Laurent-Rolle</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Garcia-Sastre</surname><given-names>A</given-names></name> (<year>2003</year>) <article-title>Inhibition of interferon signaling by dengue virus</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>100</volume>: <fpage>14333</fpage>–<lpage>14338</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-MunozJordan2">
        <label>36</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Munoz-Jordan</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Laurent-Rolle</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ashour</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Martinez-Sobrido</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ashok</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses</article-title>. <source>J Virol</source> <volume>79</volume>: <fpage>8004</fpage>–<lpage>8013</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Jones1">
        <label>37</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jones</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Davidson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hibbert</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gruenwald</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Schlaak</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression</article-title>. <source>J Virol</source> <volume>79</volume>: <fpage>5414</fpage>–<lpage>5420</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Ho1">
        <label>38</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ho</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Hung</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Weng</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>WL</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell</article-title>. <source>J Immunol</source> <volume>174</volume>: <fpage>8163</fpage>–<lpage>8172</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Young1">
        <label>39</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Young</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Didcock</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Goodbourn</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Randall</surname><given-names>RE</given-names></name> (<year>2000</year>) <article-title>Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response</article-title>. <source>Virology</source> <volume>269</volume>: <fpage>383</fpage>–<lpage>390</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Andrejeva1">
        <label>40</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Andrejeva</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Goodbourn</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Randall</surname><given-names>RE</given-names></name> (<year>2002</year>) <article-title>Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons</article-title>. <source>J Virol</source> <volume>76</volume>: <fpage>2159</fpage>–<lpage>2167</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Chambers1">
        <label>41</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chambers</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Grakoui</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name> (<year>1991</year>) <article-title>Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites</article-title>. <source>J Virol</source> <volume>65</volume>: <fpage>6042</fpage>–<lpage>6050</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Tasaki1">
        <label>42</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tasaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mulder</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Iwamatsu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Davydov</surname><given-names>IV</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons</article-title>. <source>Mol Cell Biol</source> <volume>25</volume>: <fpage>7120</fpage>–<lpage>7136</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Leung1">
        <label>43</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leung</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Qureshi</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Kerr</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Darnell</surname><given-names>JE</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Stark</surname><given-names>GR</given-names></name> (<year>1995</year>) <article-title>Role of STAT2 in the alpha interferon signaling pathway</article-title>. <source>Mol Cell Biol</source> <volume>15</volume>: <fpage>1312</fpage>–<lpage>1317</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Ashour2">
        <label>44</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ashour</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Laurent-Rolle</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Belicha-Villanueva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Plumlee</surname><given-names>CR</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Mouse STAT2 restricts early dengue virus replication</article-title>. <source>Cell Host Microbe</source> <volume>8</volume>: <fpage>410</fpage>–<lpage>421</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Emeny1">
        <label>45</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Emeny</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Morgan</surname><given-names>MJ</given-names></name> (<year>1979</year>) <article-title>Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production</article-title>. <source>J Gen Virol</source> <volume>43</volume>: <fpage>247</fpage>–<lpage>252</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Jessie1">
        <label>46</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jessie</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fong</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Devi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lam</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>KT</given-names></name> (<year>2004</year>) <article-title>Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization</article-title>. <source>J Infect Dis</source> <volume>189</volume>: <fpage>1411</fpage>–<lpage>1418</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Kou1">
        <label>47</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rodrigo</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Rose</surname><given-names>RC</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells</article-title>. <source>J Med Virol</source> <volume>80</volume>: <fpage>134</fpage>–<lpage>146</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Diamond1">
        <label>48</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diamond</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>TG</given-names></name>, <name name-style="western"><surname>Edgil</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ernst</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons</article-title>. <source>J Virol</source> <volume>74</volume>: <fpage>4957</fpage>–<lpage>4966</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Perry1">
        <label>49</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perry</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Buck</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Lada</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Schindler</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Shresta</surname><given-names>S</given-names></name> (<year>2011</year>) <article-title>STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor</article-title>. <source>PLoS Pathog</source> <volume>7</volume>: <fpage>e1001297</fpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Shresta1">
        <label>50</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shresta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kyle</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Snider</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Basavapatna</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Beatty</surname><given-names>PR</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical</article-title>. <source>J Virol</source> <volume>78</volume>: <fpage>2701</fpage>–<lpage>2710</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Sultana1">
        <label>51</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sultana</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Theodoraki</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Caplan</surname><given-names>AJ</given-names></name> (<year>2012</year>) <article-title>UBR1 promotes protein kinase quality control and sensitizes cells to Hsp90 inhibition</article-title>. <source>Exp Cell Res</source> <volume>318</volume>: <fpage>53</fpage>–<lpage>60</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Tomaic1">
        <label>52</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tomaic</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Pim</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Massimi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>MP</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD</article-title>. <source>J Virol</source> <volume>85</volume>: <fpage>3120</fpage>–<lpage>3127</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Nakatani1">
        <label>53</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakatani</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Konishi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Vassilev</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kurooka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ishiguro</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>p600, a unique protein required for membrane morphogenesis and cell survival</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>102</volume>: <fpage>15093</fpage>–<lpage>15098</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-DeMasi1">
        <label>54</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DeMasi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Huh</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Nakatani</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Munger</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Howley</surname><given-names>PM</given-names></name> (<year>2005</year>) <article-title>Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>102</volume>: <fpage>11486</fpage>–<lpage>11491</lpage>.</mixed-citation>
      </ref>
      <ref id="ppat.1003265-Huh1">
        <label>55</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huh</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>DeMasi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ogawa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nakatani</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Howley</surname><given-names>PM</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>102</volume>: <fpage>11492</fpage>–<lpage>11497</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>